Electra Therapeutics, Inc. has disclosed a series of stock transactions involving its director, Carl L. Gordon. These transactions, reported in a recent SEC filing, indicate a substantial level of investment activity that could impact the company’s standing in the biological products sector.

Electra Therapeutics, based in South San Francisco, operates under the SIC classification of Biological Products, (No Diagnostic Substances). It trades on the Nasdaq under the ticker ETRA. The company is categorized as a non-accelerated filer, smaller reporting company, and emerging growth company, reflecting its current market position.

According to the filing, Gordon acquired 98,816 shares of common stock on November 6, 2026, at a price of $7.85 per share. Following this transaction, he holds a total of 5,230,578 shares. Additionally, Gordon acquired 39,600 shares on the same day, bringing his total ownership to 2,176,579 shares. Further transactions on November 9 and November 10 saw him acquire 16,000 shares and 20,700 shares at prices of $8.24 and $8.45, respectively. His total shares following these transactions amount to 5,255,278.

The filing specifies that these securities are held directly by OrbiMed Private Investments VII, LP, and OrbiMed Genesis Master Fund, L.P., entities managed by OrbiMed Advisors, which may also have voting and investment power over the securities held. This complex ownership structure highlights the interconnected nature of investments within the sector.

These transactions may affect various stakeholders, including other investors, market analysts, and competitors within the biological products industry. The increased investment by a director may signal confidence in the company’s future performance, which could influence market perceptions and investor behavior.

Looking ahead, the filing does not specify any upcoming actions or filings related to these transactions, leaving future developments open-ended.